Antibe Therapeutics to Present at 2021 Bloom Burton & Co. Healthcare Investor Conference
April 14 2021 - 7:00AM
Business Wire
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical
stage company leveraging its hydrogen sulfide platform to develop
next-generation safer therapies for inflammation arising from a
wide range of medical conditions, is pleased to announce its
participation in the Bloom Burton & Co. Healthcare Investor
Conference being held virtually on Tuesday, April 20 and Wednesday,
April 21. Dan Legault, Antibe’s CEO, will deliver the Company’s
presentation and will discuss recent business highlights and its
growth strategy:
Date: Wednesday, April 21, 2021 Time: 11:00 am
(Eastern Time)
A link to the webcast of the presentation will be available on
the News and Events section of the Company’s website at
antibethera.com. Following the presentation, a replay of the
webcast will be available for 90 days.
The Bloom Burton & Co. Healthcare Investor Conference brings
together U.S., Canadian and international investors who are
interested in the latest developments in the Canadian healthcare
sector. Attendees will have an opportunity to obtain corporate
updates from Canada’s premier publicly traded and private companies
through presentations and private meetings.
About Antibe Therapeutics Inc.
Antibe is leveraging its proprietary hydrogen sulfide platform
to develop next-generation safer therapies to address inflammation
arising from a wide range of medical conditions. The Company’s
current pipeline includes three assets that seek to overcome the
gastrointestinal (“GI”) ulcers and bleeding associated with
nonsteroidal anti-inflammatory drugs (“NSAIDs”). Antibe’s lead
drug, otenaproxesul, is preparing to enter Phase III for the
treatment of osteoarthritis pain. Additional assets under
development include a safer alternative to opioids for
peri-operative pain, and a GI-protective alternative to low-dose
aspirin. The Company’s next target is inflammatory bowel disease
(“IBD”), a condition long in need of safer, more effective
therapies. Learn more at antibethera.com.
About Bloom Burton & Co.
Bloom Burton & Co. (Bloom Burton Securities Inc.) is a firm
dedicated to accelerating returns in the healthcare sector for both
investors and companies. Bloom Burton has an experienced team of
medical, scientific, pharmaceutical, legal and capital markets
professionals who perform a deep level of diligence, which combined
with a creative and entrepreneurial approach, assists clients in
achieving the right monetization events. Bloom Burton and its
affiliates provide capital raising, M&A advisory, equity
research, business strategy and scientific consulting, advisory on
direct investing and company creation and incubation services.
Bloom Burton Securities Inc. is a member of the Investment Industry
Regulatory Organization of Canada (IIROC) and is also a member of
the Canadian Investor Protection Fund (CIPF).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210414005233/en/
Antibe Therapeutics Inc. Christina Cameron VP Investor Relations
+1 416-577-1443 christina@antibethera.com
Antibe Therapeutics (TSX:ATE)
Historical Stock Chart
From Dec 2024 to Jan 2025
Antibe Therapeutics (TSX:ATE)
Historical Stock Chart
From Jan 2024 to Jan 2025